We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

May 19 (UPI) -- Regeneron Pharmaceuticals announced Monday it plans to purchase human genetics and biotechnology firm 23andMe from bankruptcy protection in a $256 million deal.

Me’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an ...

23andMe co-founder and CEO Anne Wokcicki won back control of the genetic-test company after a prolonged bankruptcy fight that at one point was won by Regeneron.

In response to questions about the lawsuit, Regeneron, which is based in Tarrytown in New York's lower Hudson Valley, noted in a statement that the 23andMe bankruptcy auction has been reopened and ...

23andMe filed for for Chapter 11 bankruptcy protection in March. Last month, Regeneron announced that it would purchase most of 23andMe's assets for $256 million, but it was outbid.